BeOne Medicines (BEIGF) Cash from Financing Activities (2015 - 2026)

BeOne Medicines (BEIGF) has reported Cash from Financing Activities for 12 consecutive years, with -$6.1 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities fell 117.28% year-over-year to -$6.1 million in Q2 2026; TTM through Jun 2026 was $1.1 billion, a 11839.71% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 447.66% from the prior year.
• Cash from Financing Activities was -$6.1 million for Q2 2026 at BeOne Medicines, down from $68.6 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $961.3 million in Q3 2025 and troughed at -$110.4 million in Q4 2022.
• A 5-year average of $95.2 million and a median of $17.8 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities plunged 163.86% in 2023 and jumped 7491.79% in 2025, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$110.4 million in 2022, then jumped by 414.45% to $347.0 million in 2023, then tumbled by 101.3% to -$4.5 million in 2024, then surged by 2243.07% to $96.9 million in 2025, then sank by 106.25% to -$6.1 million in 2026.
• The last three Cash from Financing Activities figures came in at -$6.1 million (Q2 2026), $68.6 million (Q1 2026), and $96.9 million (Q4 2025), per Business Quant data.